Trastuzumab deruxtecan

Trastuzumabinfo-icon deruxtecan (Enhertu) is an antibody-drug conjugate approved to treat people with metastatic, HER2-postive, hormone receptor-negative breast cancer that has grown after at least two past treatments.

How trastuzumab deruxtecan is given

Trastuzumabinfo-icon deruxtecan is given by veininfo-icon once every 3 weeks at your doctor’s office or infusioninfo-icon center. Your care team determines the doseinfo-icon by your weight, and you’ll get it over about 30 minutes (90 minutes for your first infusion). Treatment can continue until the cancer grows or spreads to other parts of the body or you and your doctor decide to stop because of side effects.

Side effects and things to remember

In the clinicalinfo-icon studies of trastuzumabinfo-icon deruxtecan, the people who took part reported these common side effects that you may experience

In rare cases, some people developed a very serious lung conditioninfo-icon called interstitial lung disease. On scans, this disease looks like scarring or inflammationinfo-icon of the lungs. This condition can be fatal. You should report any lung problems you have while taking this medicineinfo-icon to your doctor immediately, including

  • cough
  • trouble breathing
  • shortness of breath
  • fever

Like other HER2-targeting medicines, trastuzumab deruxtecan can also affect your heart function. Your doctor will watch for problems in your heart, but let them know if you have symptoms such as sudden weight gain, swelling, dizziness, or if you faint.

Trastuzumab deruxtecan may be dangerous to a fetus if taken during or before a pregnancy. You should not take it if you are pregnant or breastfeeding, and you should take steps to avoid getting pregnant while on trastuzumab deruxtecan. Men taking trastuzumab deruxtecan should also take steps to avoid getting their partner pregnant. 

March 25, 2021